Search

Vera N Simonenko

age ~65

from Germantown, MD

Get Report
Also known as:
  • Simonenko Vera
Phone and address:
13020 Woodcutter Cir APT 51, Germantown, MD 20876
Connected to:

Vera Simonenko Phones & Addresses

  • 13020 Woodcutter Cir APT 51, Germantown, MD 20876
  • Gaithersburg, MD
  • 1003 Royal Oaks Dr, Birmingham, AL 35244
  • 309 Royal Oaks Dr, Birmingham, AL 35244
  • Hoover, AL

Work

  • Position:
    Professional/Technical

Education

  • Degree:
    High school graduate or higher

Us Patents

  • Combinations Of Tgfbeta And Cox-2 Inhibitors And Methods For Their Therapeutic Application

    view source
  • US Patent:
    20130225655, Aug 29, 2013
  • Filed:
    May 4, 2011
  • Appl. No.:
    13/695073
  • Inventors:
    Patrick Y. Lu - Rockville MD, US
    Vera Simonenko - Germantown MD, US
    David Evans - North Potomac MD, US
    John J. Xu - Germantown MD, US
  • International Classification:
    A61K 31/713
    C07H 21/02
    A61K 45/06
  • US Classification:
    514 44 A
  • Abstract:
    The present invention provides compositions and methods for using combinations of TGFβ1 and Cox-2 inhibitors and TGFβ1 and Hoxb13 inhibitors for the treatment of various medical conditions, including skin scaring due to trauma wounds and surgery, corneal and retina scaring due to injury and surgery, internal organ scaring due to injury and surgery, heart tissue scaring due to heart attack and surgery, and lung, liver, and kidney fibrosis due to inflammation and injury. One example is to use siRNA inhibitors to silence TGFβ1 and Cox-2 at the same time, resulting in significant less scar formation.

  • Multi-Targeted Rnai Therapeutics For Scarless Wound Healing Of Skin

    view source
  • US Patent:
    20100319074, Dec 16, 2010
  • Filed:
    Nov 6, 2008
  • Appl. No.:
    12/741645
  • Inventors:
    Patrick Y. Lu - Rockville MD, US
    Ling Li - Port St. Lucie FL, US
    Vera Simonenko - Germantown MD, US
  • Assignee:
    SIR NAOMICS, INC. - Gaithersburg MD
  • International Classification:
    A61K 31/713
    C07H 21/04
    A61P 17/02
    A61K 49/00
  • US Classification:
    800 3, 536 245, 514 44 A
  • Abstract:
    The present invention provides small interfering RNA (siRNA) molecules, compositions containing them, and methods of using them for improvement of skin scarless wound healing and other skin conditions, such as psoriasis and lupus-caused cutaneous lesions. The invention includes siRNA molecules and compositions containing them that inhibit the expression of one or more genes that promote pathological or undesired processes in wound healing and methods of using them.

  • Combinations Of Sirnas With Sirnas Against Sulf2 Or Gpc3 For Use In Treating Cancer

    view source
  • US Patent:
    20220333108, Oct 20, 2022
  • Filed:
    Apr 1, 2022
  • Appl. No.:
    17/711975
  • Inventors:
    - Gaithersburg MD, US
    John XU - Gaithersburg MD, US
    Patrick Y. LU - Gaithersburg MD, US
    Vera SIMONENKO - Gaithersburg MD, US
  • International Classification:
    C12N 15/113
    A61P 35/00
  • Abstract:
    Compositions and methods are provided for silencing the Sulf2 and/or GPC3 genes in vivo. Potent siRNA sequences are provided that silence regions of the Sulf2 and GPC3 genes that are identical in human, mice and non-human primates. Combinations of siRNAs also are provided that result in additivity or synergy with silencing of Sulf2 and/or GPC3. Silencing SULF2+TGFβ1 showed a dramatic effect against cancer growth in vitro and in vivo.

  • Methods Of Cancer Treatment By Delivery Of Sirnas Against Bclxl And Mcl1 Using A Polypeptide Nanoparticle

    view source
  • US Patent:
    20220288228, Sep 15, 2022
  • Filed:
    Mar 14, 2022
  • Appl. No.:
    17/694224
  • Inventors:
    - Gaithersburg MD, US
    Vera SIMONENKO - Gaithersburg MD, US
  • International Classification:
    A61K 47/69
    A61K 33/243
    A61K 31/713
    C12N 15/113
  • Abstract:
    Compositions and methods are provided for the silencing of the BCLxL and MCL1 genes. Specifically, siRNA compositions are provided that contain siRNA molecules that target the BCLxL and MCL1 genes. Methods for using these compositions for treating cancer also are provided.

  • Composition And Methods Of Rnai Prophylactics And Therapeutics For Treatment Of Severe Acute Respiratory Infection Caused By 2019 Novel Coronavirus (2019-Ncov)

    view source
  • US Patent:
    20210246448, Aug 12, 2021
  • Filed:
    Jan 25, 2021
  • Appl. No.:
    17/157920
  • Inventors:
    - Gaithersburg MD, US
    Xueping CHEN - Guangzhou, CN
    Patrick Y. LU - Potomac MD, US
    Vera SIMONENKO - Gaithersburg MD, US
    David EVANS - Gaithersburg MD, US
    John XU - Gaithersburg MD, US
    Deling WANG - Suzhou, CN
    Alan LU - Gaithersburg MD, US
  • International Classification:
    C12N 15/113
    A61K 47/69
    A61P 31/14
    A61K 47/28
  • Abstract:
    Compositions and methods for development of potent siRNA therapeutics for prevention and treatment of Corona Virus (2019-nCoV; COVID-19) infections are provided. The compositions include a pharmaceutical composition comprising siRNA cocktails that target critical viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Administration methods for prevention and treatment are provided, including airway instillation, subcutaneous injections and nebulizer aerosolization.

  • Composition And Methods Of Controllable Co-Coupling Polypeptide Nanoparticle Delivery System For Nucleic Acid Therapeutics

    view source
  • US Patent:
    20210162067, Jun 3, 2021
  • Filed:
    Nov 24, 2020
  • Appl. No.:
    17/103386
  • Inventors:
    - Gaithersburg MD, US
    Patrick Y. LU - Gaithersburg MD, US
    Vera SIMONENKO - Gaithersburg MD, US
    David M. EVANS - Gaithersburg MD, US
  • International Classification:
    A61K 47/69
    C07K 4/00
    A61K 48/00
    C12N 15/113
  • Abstract:
    The present invention provides certain peptides and polypeptides useful in the preparation of nanoparticles for delivering nucleic acids and pharmaceutical drugs to mammalian cells and to humans and other mammals. It further provides methods for making the peptides, polypeptides, and nanoparticles and methods for using the nanoparticles.

  • Pharmaceutical Compositions And Methods Of Use For Activation Of Human Fibroblast And Myofibroblast Apoptosis

    view source
  • US Patent:
    20200392507, Dec 17, 2020
  • Filed:
    Oct 30, 2017
  • Appl. No.:
    16/343309
  • Inventors:
    Jia Zhou - , US
    Qingfeng Li - , US
    - Gaithersburg MD, US
    Qingfeng Li - Shanghai, CN
    Vera Simonenko - Gaithersburg MD, US
  • Assignee:
    Sirnaomics, Inc. - Gaithersburg MD
  • International Classification:
    C12N 15/113
    A61K 31/713
    A61K 47/34
  • Abstract:
    The current invention provides a method of activating fibroblast and myofibroblast apoptosis in a tissue of a mammal, comprising administering to the tissue a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGFB1 protein in a mammalian cell, an siRNA molecule that binds to an mRNA that codes for COX-2 protein in a mammalian cell, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable histidine-lysine polymer. The invention also provides additional methods for using this composition.

  • Gemcitabine Derivatives For Cancer Therapy

    view source
  • US Patent:
    20200108089, Apr 9, 2020
  • Filed:
    Mar 19, 2018
  • Appl. No.:
    16/495294
  • Inventors:
    - Suzhou, CN
    - Gaithersburg MD, US
    Parker J. Guan - Germantown MD, US
    John J. Xu - Germantown MD, US
    Vera Simonenko - Germantown MD, US
    Tom Zhong - Suzhou, CN
  • Assignee:
    Suzhou Sirnaomics Biopharmaceuticals Co., Ltd. - Suzhou
    Sirnaomics, Inc. - Gaithersburg MD
  • International Classification:
    A61K 31/7068
    A61K 31/713
    C12N 15/113
    A61K 31/575
    A61K 47/64
    A61P 35/00
  • Abstract:
    The present invention provides pharmaceutical compositions comprising the chemotherapy drug gemcitabine (GEM) and certain derivatives, a taurocholic acid (TCA) formulation, and a Histidine-Lysine Polymer (HKP) conjugate, for enhancement of RNAi cancer therapeutics.
Get Report for Vera N Simonenko from Germantown, MD, age ~65
Control profile